Current and historical daily PE Ratio for Cellectis SA (
) from 2015 to May 01 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Cellectis stock (CLLS) PE ratio as of May 01 2024 is 0.
More Details
Cellectis SA (CLLS) PE Ratio (TTM) Chart
Cellectis SA (CLLS) PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Total 1218
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Cellectis PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-01 | At Loss | 2024-02-26 | At Loss |
| 2024-04-29 | At Loss | 2024-02-23 | At Loss |
| 2024-04-26 | At Loss | 2024-02-22 | At Loss |
| 2024-04-25 | At Loss | 2024-02-21 | At Loss |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-04-01 | At Loss | 2024-01-25 | At Loss |
| 2024-03-28 | At Loss | 2024-01-24 | At Loss |
| 2024-03-27 | At Loss | 2024-01-23 | At Loss |
| 2024-03-26 | At Loss | 2024-01-22 | At Loss |
| 2024-03-25 | At Loss | 2024-01-19 | At Loss |
| 2024-03-22 | At Loss | 2024-01-18 | At Loss |
| 2024-03-21 | At Loss | 2024-01-17 | At Loss |
| 2024-03-20 | At Loss | 2024-01-16 | At Loss |
| 2024-03-19 | At Loss | 2024-01-12 | At Loss |
| 2024-03-18 | At Loss | 2024-01-11 | At Loss |
| 2024-03-15 | At Loss | 2024-01-10 | At Loss |
| 2024-03-14 | At Loss | 2024-01-09 | At Loss |
| 2024-03-13 | At Loss | 2024-01-08 | At Loss |
| 2024-03-12 | At Loss | 2024-01-05 | At Loss |
| 2024-03-11 | At Loss | 2024-01-04 | At Loss |
| 2024-03-08 | At Loss | 2024-01-03 | At Loss |
| 2024-03-07 | At Loss | 2024-01-02 | At Loss |
| 2024-03-06 | At Loss | 2023-12-29 | At Loss |
| 2024-03-05 | At Loss | 2023-12-28 | At Loss |
| 2024-03-04 | At Loss | 2023-12-27 | At Loss |
| 2024-03-01 | At Loss | 2023-12-26 | At Loss |
| 2024-02-29 | At Loss | 2023-12-22 | At Loss |
| 2024-02-28 | At Loss | 2023-12-21 | At Loss |
| 2024-02-27 | At Loss | 2023-12-20 | At Loss |
Cellectis SA (CLLS) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Cellectis SA
ISIN : US15117K1034
Share Class Description:
CLLS: ADRCompare
Compare
Traded in other countries / regions
ALCLS.FranceCLLS.USA0WA2.UKZVAA.Germany IPO Date
2015-03-25Description
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers